mobilizing_organizationsgenerating_ideasallocating_resourcesdriving_innovation
Issuance of U.S. Patent Number 8,831,729 to EndoStim, Inc.
09 Sep, 2014
News
On September 9, 2014, the USPTO issued U.S. Patent Number 8,831,729 to EndoStim, Inc., which was successfully prosecuted by Novel IP.
 
The '729 patent is directed towards systems and methods for treating gastroesophageal reflux disease that includes minimally invasively implanting a stimulating device in a patient's esophagus in the region proximate the lower espohageal sphincter (LES).  The patient is provided with a questionnaire related to his disease via an online service.  The questionnaire is accessed on a mobile device, such as a cell phone, or on a computer with network access.  The data from the sensors and the answers from the questionnaire are analyzed together by a health care provider using the online service. The data and answers are used to program the stimulating device, via the mobile device or computer, to optimize treatment.
 
Independent Claim 1 describes "a method of treating gastroesophageal reflux disease (GERD) in a patient having a lower espohageal sphincter (LES) comprising: implanting a stimulation device proximate the LES wherein said stimulation device is programmable and provides electrical stimulation to the LES to produce a contraction of said LES; measuring a pH in the patient's esophagus and generating pH data; transmitting said pH data to a processor housed within a computing device external to the patient and storing said pH data within said computing device; obtaining information relating to the patient's symptoms arising from the patient's GERD; analyzing said pH data in relation to said information to generate programming parameters; and programming said stimulation device using said programming parameters wherein said programming step comprises establishing fixed start times for initiating said electrical stimulation and fixed end times for terminating said electrical stimulation."